NCT04724031Active, not recruitingNot Applicable
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Hellenic Cooperative Oncology Group1 site in 1 country150 target enrollmentStarted: November 1, 2019Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Evaluation of Progression Free Survival
Study Overview
Brief Summary
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
Detailed Description
A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •women >18 years old with advanced high grade ovarian cancer
Exclusion Criteria
- Not provided
Arms & Interventions
One cohort
women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
Intervention: PARP inhibitor (Drug)
Outcomes
Primary Outcomes
Evaluation of Progression Free Survival
Time Frame: 12/2022
Secondary Outcomes
- Assessment of the safety profile of olaparib in women with advanced high grade ovarian cancer(12/2021)
- Assessment of the safety profile of niraparib in women with advanced high grade ovarian cancer(12/2021)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Real-world Data in Patients With Breast Cancer Treated With AbemaciclibBreast CancerNCT04985058Hellenic Cooperative Oncology Group108
Unknown
Not Applicable
Advanced Refractory Solid Tumors With TP53 Mutations Register StudySolid Tumor, AdultNCT03927599Tianjin Medical University Second Hospital100
Completed
Not Applicable
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT03896984Bayer346
Recruiting
Phase 2
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)Sarcoma,Soft TissueSarcoma of BoneSarcomaNCT06074692Ruijin Hospital86
Recruiting
Not Applicable
Drug-drug Interactions With Anti-tuberculous DrugsDrug-drug InteractionNCT06381375Cairo University400